IL128769A0 - Expression of an exogenous gene by us of a non-mammalian dna virus - Google Patents
Expression of an exogenous gene by us of a non-mammalian dna virusInfo
- Publication number
- IL128769A0 IL128769A0 IL12876997A IL12876997A IL128769A0 IL 128769 A0 IL128769 A0 IL 128769A0 IL 12876997 A IL12876997 A IL 12876997A IL 12876997 A IL12876997 A IL 12876997A IL 128769 A0 IL128769 A0 IL 128769A0
- Authority
- IL
- Israel
- Prior art keywords
- expression
- exogenous gene
- dna virus
- mammalian dna
- mammalian
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1758—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals p53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14145—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
- C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Marine Sciences & Fisheries (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2629796P | 1996-09-11 | 1996-09-11 | |
PCT/US1997/016041 WO1998011243A2 (en) | 1996-09-11 | 1997-09-11 | Expression of an exogenous gene in a mammalian cell by use of a non-mammalian dna virus having an altered coat protein |
Publications (1)
Publication Number | Publication Date |
---|---|
IL128769A0 true IL128769A0 (en) | 2000-01-31 |
Family
ID=21831009
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL12876997A IL128769A0 (en) | 1996-09-11 | 1997-09-11 | Expression of an exogenous gene by us of a non-mammalian dna virus |
Country Status (9)
Country | Link |
---|---|
US (2) | US6338953B1 (de) |
EP (1) | EP0931159A2 (de) |
JP (1) | JP2001508645A (de) |
KR (1) | KR20000036051A (de) |
AU (1) | AU4340397A (de) |
BR (1) | BR9712978A (de) |
CA (1) | CA2264966A1 (de) |
IL (1) | IL128769A0 (de) |
WO (1) | WO1998011243A2 (de) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6183993B1 (en) * | 1996-09-11 | 2001-02-06 | The General Hospital Corporation | Complement-resistant non-mammalian DNA viruses and uses thereof |
GB9708698D0 (en) * | 1997-04-29 | 1997-06-18 | Imperial College | Materials for therapy |
US6989264B2 (en) * | 1997-09-05 | 2006-01-24 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
US6346415B1 (en) * | 1997-10-21 | 2002-02-12 | Targeted Genetics Corporation | Transcriptionally-activated AAV inverted terminal repeats (ITRS) for use with recombinant AAV vectors |
AU2006225325B2 (en) * | 1997-12-22 | 2010-04-22 | The University Of Tennessee Research Corporation | Recombinant Rhabdovirus containing a heterologous fusion protein |
US6448390B1 (en) | 1998-05-20 | 2002-09-10 | The University Of Tennessee Research Corporation | Stable envelope proteins for retroviral, viral and liposome vectors and use in gene drug therapy |
EP1100946A1 (de) * | 1998-07-24 | 2001-05-23 | Aventis Pharma S.A. | Von bakulovirus abgeleiteten vektoren und deren anwendung zum transfert von nukleinensäuren nach nervenzellen aus vertebraten |
FR2781503B1 (fr) * | 1998-07-24 | 2003-01-31 | Rhone Poulenc Rorer Sa | Nouveaux vecteurs derives de baculovirus et utilisation pour le transfert d'acides nucleiques dans les cellules nerveuses |
US7018628B1 (en) | 1998-07-24 | 2006-03-28 | Aventis Pharma S.A. | Vectors derived from baculovirus and use for transferring nucleic acids into nerve cells of vertebrates |
US6793926B1 (en) * | 1999-05-27 | 2004-09-21 | Genovo, Inc. | Methods for production of a recombinant adeno-associated virus |
GB9919409D0 (en) * | 1999-08-18 | 1999-10-20 | Univ Oxford Brookes | Baculovirus expression system |
WO2002013861A2 (en) * | 2000-08-11 | 2002-02-21 | Favrille, Inc. | Method and composition for altering a t cell mediated pathology |
AU2001284791A1 (en) | 2000-08-11 | 2002-02-25 | Boyce Thompson Institute For Plant Research Inc. | Gp64-null baculoviruses pseudotyped with heterologous envelope proteins |
US6911204B2 (en) | 2000-08-11 | 2005-06-28 | Favrille, Inc. | Method and composition for altering a B cell mediated pathology |
AU2002256274A1 (en) * | 2001-04-18 | 2002-11-05 | Genstar Therapeutics Corp. | Minimal adenoviral vectors for immunization |
EP1395293B1 (de) | 2001-05-14 | 2009-07-22 | Gbp Ip, Llc | Lentivirale vektoren kodierend für gerinnungsfaktoren für die gentherapie |
GB0119852D0 (en) * | 2001-08-15 | 2001-10-10 | Univ York | Baculovirus |
US6863884B2 (en) * | 2002-05-01 | 2005-03-08 | Cell Genesys, Inc. | Pseudotyped retroviral vectors |
US7416890B2 (en) | 2002-09-25 | 2008-08-26 | Osaka Industrial Promotion Organization | Baculovirus vector, method of producing thereof and method of gene transfer |
AU2003266628A1 (en) * | 2002-09-25 | 2004-04-19 | Osaka Industrial Promotion Organization | Baculovirus vector, method of constructing baculovirus vector and gene transfer method |
PT2248899E (pt) | 2003-03-19 | 2015-09-23 | Biogen Ma Inc | Proteína de ligação do receptor nogo |
ES2395094T3 (es) | 2004-06-24 | 2013-02-08 | Biogen Idec Ma Inc. | Tratamiento de afecciones que implican la desmielinización |
EP2238986A3 (de) | 2005-07-08 | 2010-11-03 | Biogen Idec MA Inc. | Sp35-Antikörper und Verwendungen dafür |
US9333249B2 (en) | 2006-02-09 | 2016-05-10 | Educational Foundation Jichi Medical University | Recombinant baculovirus vaccine |
TWI477602B (zh) | 2006-02-09 | 2015-03-21 | Educational Foundation Jichi Medical Univ | Novel viral vector |
US20080044855A1 (en) * | 2006-03-22 | 2008-02-21 | Yan Xu | System for regulated and enhanced baculovirus mediated transient transgene expression in mammalian cells |
US20070292917A1 (en) * | 2006-06-20 | 2007-12-20 | Invitrogen Corporation | Composition and methods for expressing reporter molecules in mammalian cells |
US8128926B2 (en) | 2007-01-09 | 2012-03-06 | Biogen Idec Ma Inc. | Sp35 antibodies and uses thereof |
JP2008263964A (ja) * | 2007-03-29 | 2008-11-06 | Yamaguchi Univ | コウモリ由来細胞株 |
CA2701189C (en) * | 2007-10-11 | 2017-05-16 | Biogen Idec Ma Inc. | Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell survival via administration of lingo-1 antagonists and trkb agonists |
JP5754046B2 (ja) * | 2007-11-08 | 2015-07-22 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | 脱髄を伴う状態の治療におけるlingo−4アンタゴニストの使用 |
WO2010005570A2 (en) * | 2008-07-09 | 2010-01-14 | Biogen Idec Ma Inc. | Compositions comprising antibodies to lingo or fragments thereof |
AU2013247424A1 (en) * | 2012-04-10 | 2014-10-30 | Agency For Science, Technology And Research | Methods for bladder cancer therapy using baculoviral vectors |
EA030716B1 (ru) | 2012-05-14 | 2018-09-28 | Байоджен Ма Инк. | Антагонисты lingo-2 для лечения заболеваний, в которых участвуют двигательные нейроны |
US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
US10435467B2 (en) | 2015-01-08 | 2019-10-08 | Biogen Ma Inc. | LINGO-1 antagonists and uses for treatment of demyelinating disorders |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
AU2019346549A1 (en) * | 2018-09-24 | 2021-04-15 | Krystal Biotech, Inc. | Compositions and methods for the treatment of netherton syndrome |
WO2023150590A2 (en) * | 2022-02-02 | 2023-08-10 | FibroBiologics | Therapeutic use of fibroblasts to stimulate the immune system |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4745051A (en) | 1983-05-27 | 1988-05-17 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
US4879236A (en) | 1984-05-16 | 1989-11-07 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
FR2579224B1 (fr) | 1985-03-25 | 1987-05-22 | Genetica | Procede de preparation microbiologique de la serum-albumine humaine |
US5004687A (en) | 1985-05-21 | 1991-04-02 | University Of Georgia Research Foundation, Inc. | Insect virus vector with broadened host range |
US5106741A (en) | 1985-12-20 | 1992-04-21 | The Upjohn Company | Tissue plasminogen activator (TPA) analogs |
CA2104396C (en) | 1991-02-19 | 2000-10-10 | Jiing-Kuan Yee | Viral particles having altered host range |
US5476781A (en) | 1991-02-19 | 1995-12-19 | University Of Florida Research Foundation, Inc. | Entomopoxvirus spheroidin gene sequences |
DE4407859C1 (de) | 1994-03-04 | 1995-03-02 | Max Planck Gesellschaft | Vektor für die leberspezifische Gentherapie |
FR2718150B1 (fr) | 1994-03-29 | 1996-04-26 | Rhone Poulenc Rorer Sa | Virus recombinants, préparation et utilisation en thérapie génique. |
CN1172435A (zh) | 1994-09-23 | 1998-02-04 | 综合医院公司 | 使用非哺乳动物dna病毒在哺乳动物细胞中表达外源基因 |
-
1997
- 1997-09-11 CA CA002264966A patent/CA2264966A1/en not_active Abandoned
- 1997-09-11 US US08/927,317 patent/US6338953B1/en not_active Expired - Lifetime
- 1997-09-11 WO PCT/US1997/016041 patent/WO1998011243A2/en not_active Application Discontinuation
- 1997-09-11 AU AU43403/97A patent/AU4340397A/en not_active Abandoned
- 1997-09-11 IL IL12876997A patent/IL128769A0/xx unknown
- 1997-09-11 BR BR9712978-0A patent/BR9712978A/pt not_active IP Right Cessation
- 1997-09-11 KR KR1019997002049A patent/KR20000036051A/ko not_active Application Discontinuation
- 1997-09-11 JP JP51383598A patent/JP2001508645A/ja active Pending
- 1997-09-11 EP EP97941509A patent/EP0931159A2/de not_active Withdrawn
-
2000
- 2000-02-28 US US09/514,953 patent/US6190887B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
WO1998011243A9 (en) | 2001-06-21 |
WO1998011243A2 (en) | 1998-03-19 |
KR20000036051A (ko) | 2000-06-26 |
AU4340397A (en) | 1998-04-02 |
US6338953B1 (en) | 2002-01-15 |
EP0931159A2 (de) | 1999-07-28 |
JP2001508645A (ja) | 2001-07-03 |
BR9712978A (pt) | 2000-04-18 |
US6190887B1 (en) | 2001-02-20 |
WO1998011243A3 (en) | 1998-05-07 |
CA2264966A1 (en) | 1998-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL128769A0 (en) | Expression of an exogenous gene by us of a non-mammalian dna virus | |
AU5253998A (en) | Diminishing viral gene expression by promoter replacement | |
AU4563300A (en) | Regulation of viral gene expression | |
HUP0101225A3 (en) | Control of gene expression | |
GB9915126D0 (en) | Control of gene expression | |
AU7131600A (en) | Acid-inducible promoters for gene expression | |
AU3206697A (en) | Ribozyme-mediated gene replacement | |
HUP0001817A3 (en) | Chlorella virus promoters | |
AU6595986A (en) | Aids virus gene expression | |
AU4425397A (en) | Antisense gene therapy for rna viruses | |
HUP9900750A3 (en) | Promoters for gene expression | |
AU1302999A (en) | Ketoreductase gene and protein from yeast | |
AU2208199A (en) | Cloning of a high growth gene | |
AU4858897A (en) | Flax promoters for manipulating gene expression | |
AU6221996A (en) | Oligonucleotides specific for hepatitis c virus | |
AUPO947997A0 (en) | Method of regulating gene expression | |
AU5397398A (en) | Process for the expression of genes of the dengue viruses | |
GB9506051D0 (en) | Gene expression | |
AU8658798A (en) | Procedure for preparing enriched gene expression libraries | |
GB9910413D0 (en) | Novel promoter of gene expression | |
AU5561599A (en) | Dna promoter sequence for gene expression | |
AU7336296A (en) | Human hepatitis b virus dna | |
AU7428598A (en) | Genetic method for producing virus resistant organisms | |
AU5676398A (en) | Method for detecting exogenous gene expression | |
AUPP058797A0 (en) | Novel gene |